Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

Interest Coverage 2.12
CBST's Interest Coverage is ranked lower than
95% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 2.12 )
Ranked among companies with meaningful Interest Coverage only.
CBST' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.12
Current: 2.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

» CBST's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2014

CBST Guru Trades in Q2 2014

Ken Fisher 36,450 sh (New)
Vanguard Health Care Fund 1,467,542 sh (+10.91%)
Steven Cohen 394,200 sh (unchged)
Murray Stahl 24,000 sh (unchged)
Lee Ainslie Sold Out
George Soros Sold Out
Pioneer Investments 358,881 sh (-2.62%)
Chuck Royce 211,600 sh (-3.77%)
RS Investment Management 390,565 sh (-22.64%)
Jim Simons 47,420 sh (-74.92%)
» More
Q3 2014

CBST Guru Trades in Q3 2014

Vanguard Health Care Fund 1,977,342 sh (+34.74%)
Pioneer Investments 338,388 sh (unchged)
Murray Stahl 24,000 sh (unchged)
RS Investment Management Sold Out
Jim Simons Sold Out
Ken Fisher 34,775 sh (-4.60%)
Chuck Royce 197,980 sh (-6.44%)
Steven Cohen 340,200 sh (-13.70%)
» More
Q4 2014

CBST Guru Trades in Q4 2014

First Eagle Investment 20,000 sh (New)
Prem Watsa 20,200 sh (New)
Eric Mindich 1,904,073 sh (New)
Mario Gabelli 236,700 sh (New)
Paul Singer 539,000 sh (New)
George Soros 120,000 sh (New)
First Eagle Investment 200 sh (unchged)
Vanguard Health Care Fund 1,977,342 sh (unchged)
Pioneer Investments Sold Out
Steven Cohen Sold Out
Chuck Royce Sold Out
Murray Stahl 19,000 sh (-20.83%)
Ken Fisher 2,150 sh (-93.82%)
» More
Q1 2015

CBST Guru Trades in Q1 2015

George Soros Sold Out
Murray Stahl Sold Out
Vanguard Health Care Fund Sold Out
Mario Gabelli Sold Out
Ken Fisher Sold Out
First Eagle Investment Sold Out
Prem Watsa Sold Out
Eric Mindich Sold Out
Paul Singer Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CBST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Traded in other countries:CU6.Germany,

Cubist Pharmaceuticals, Inc., was incorporated as a Delaware corporation in 1992. It is a biopharmaceutical company that provides research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Its products and product candidates are used, or are being developed to be used, in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. Its currently marketed products include CUBICIN, DIFICID, and DIFICID. CUBICIN is a once-daily, bactericidal, I.V. antibiotic with activity against certain Gram-positive organisms, including MRSA. CUBICIN is approved in more than 50 countries including the U.S., EU, and Japan. DIFICID is a macrolide antibiotic for the treatment of CDAD. ENTEREG is an oral, peripherally-acting mu opioid receptor antagonist. The Company currently relies on a global network of third party contract manufacturers to manufacture its starting materials, active pharmaceutical ingredients, or APIs, and finished drug products for commercial sale. Its competitors include Abbott, Shionogi & Co., Ltd., Pfizer, Inc., King Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., ViroPharma Incorporated, among others. The Company's current and contemplated activities, and the products and processes that result from such activities, are subject to substantial government regulation.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $1,165
EPS (TTM) $ 0.81
Short Percentage of Float9.89%
52-Week Range $58.50 - 101.99
Shares Outstanding (Mil)76.30

Analyst Estimate

Dec14 Dec15 Dec16 Dec17
Revenue (Mil $) 1,202 1,401 1,568 1,642
EPS ($) 1.28 2.35 4.09 5.70
EPS w/o NRI ($) 1.28 2.35 4.09 5.70
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($)
» More Articles for CBST


Articles On GuruFocus.com
Mario Gabelli's Top 5 Stock Picks Mar 30 2015 
Prem Watsa Buys 2 and Sells 1 Stock in Fourth Quarter Feb 16 2015 
Mario Gabelli's Top 5 New Stock Buys of Q4 Feb 05 2015 
Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
Cubist Pharmaceutical - Acutely Aware May 09 2010 

More From Other Websites
FDA approves Cubists' drug for antibiotic-resistant bacteria Dec 19 2014
Cubist sales force seen as potential boon for Merck intestinal drug Dec 10 2014
Cubist sales force seen as potential boon for Merck intestinal drug Dec 09 2014
Merck committed to Cubist after patent losses Dec 09 2014
Merck says still plans Cubist purchase, despite patent setback Dec 09 2014
After Big Cubist Buy, Are These 2 Stocks Next to Be Acquired? Dec 09 2014
Merck dives into 'superbug' chase with Cubist Dec 08 2014
Merck to buy Cubist Pharmaceuticals for $8.4 billion Dec 08 2014
Court rules Hospira can launch generic Cubicin in 2016 Dec 08 2014
US STOCKS-Wall St falls with energy shares; global data disappoints Dec 08 2014
Cubist options unusually active before Merck deal Dec 08 2014
US STOCKS-Wall St flat after Japan, China data; biotechs climb Dec 08 2014
US STOCKS-Wall St slips after Japan, China data; energy drags Dec 08 2014
US STOCKS-Wall St to open lower after Japan, China data Dec 08 2014
Merck, Cubist Agree to $9.5 Billion Acquisition Dec 08 2014
US STOCKS-Futures lower after China, Japan data disappoints Dec 08 2014
US STOCKS-Futures fall after soft China, Japan data Dec 08 2014
Merck buying Cubist Pharmaceuticals for $8.4B Dec 08 2014
Merck takes aim at superbugs, to buy Cubist in $9.5 bln deal Dec 08 2014
PRESS DIGEST- Financial Times - Dec 8 Dec 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)